Biogen
Q4 2022 Earnings Call
Feb 15, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. My name is Bettina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2022 earnings call and business update. [Operator instructions] After the speakers' remarks, there will be a question-and-answer session.
[Operator instructions] I would now like to turn the conference over to Mr. Mike Hencke, head of investor relations. Mr. Hencke, you may begin your conference.
Michael Hencke -- Head of Investor Relations
Thank you. Good morning and welcome to Biogen's fourth quarter and full year 2022 earnings call. Before we begin, I encourage everyone to go to the investors section of biogen.com to find the earnings release and related financial tables, including our GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today. Our GAAP financials are provided in Tables 1 and 2, and Table 4 includes a reconciliation of our GAAP to non-GAAP financial results.
We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We have also posted slides on our website that follow the discussions related to this call. I would like to point out that we will be making forward-looking statements, which are based on our expectations. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.
I encourage you to consult the risk factors discussed in our SEC filings for additional detail. On today's call, I am joined by our president and chief executive officer, Christopher Viehbacher; Dr. Priya Singhal, head of development; and our CFO, Mike McDonnell. As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question.
I'll now turn the call over to Chris.
Christopher Viehbacher -- President and Chief Executive Officer
Thank you, Mike. Good morning, everybody, and thanks for joining us. It's a pleasure to welcome you here today. This is my first earnings call since joining Biogen.
So, clearly, Biogen has a strong legacy as one of the pioneers in biotechnology, and there's clearly a strong foundation to build upon. Equally, there's an urgent need to restore growth to the company. We have a great opportunity ahead with the potential launch of two important near-term launches with Alzheimer's and depression, and we have several pipeline programs. We'll be covering a lot more about how we intend to return to growth.